Total Funding
$1.2M
Employee Range
1-10
Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Ducentis' target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system.
Ducentis BioTherapeutics data powered by:
Share
Ducentis BioTherapeutics data powered by:
Ducentis BioTherapeuticsOverall Ranking
National Rank
Share
Loading...
In United Kingdom
Top null%out of exits
Regional Rank
Share
Loading...
In Western Europe
Top null%out of exits
Ducentis BioTherapeuticsIndustry Rankings in
Healthtech
City Rank
Share
1st
In Witney
Top 100%out of 1 exits
National Rank
Share
4th
In United Kingdom
Top 20%out of 21 exits
Regional Rank
Share
8th
In Western Europe
Top 15%out of 57 exits
Ducentis BioTherapeuticsSubindustry Rankings in
BiotechnologyCity Rank
Share
1st
In Witney
Top 100%out of 1 exits
National Rank
Share
4th
In United Kingdom
Top 23%out of 18 exits
Regional Rank
Share
7th
In Western Europe
Top 17%out of 42 exits
Special Awards
Exit Explorer
Had an exit eventrankings by:
Ducentis BioTherapeuticsSB Rank Evolution
Not enough data points to display the chart.
Ducentis BioTherapeuticsexitComparison
National Ranking (undefined)
Loading...
...
Regional Ranking (undefined)
Loading...
...
Global Ranking (WorldWide)
Loading...
...
Industry Ranking (undefined)
Loading...
...
SubIndustry Ranking (undefined)
Loading...
...
See all ranked entities with a premium subscription
Get Pro